Sviridov D D, Ehnholm C, Tenkanen H, Safonova I G, Repin V S
Institute of Experimental Cardiology, Cardiology Research Center, Moscow, Russia.
FEBS Lett. 1992 Jun 1;303(2-3):202-4. doi: 10.1016/0014-5793(92)80519-m.
Treatment of 125I-labelled high-density lipoprotein ([125I]HDL3) with monospecific polyclonal antibodies against apolipoproteins A-I and A-II resulted in a dose-dependent inhibition of the [125I]HDL3 binding to isolated human small intestine epithelial cells by 25% and 50%, respectively. Both antibodies also inhibited intracellular degradation of [125I]HDL3 by 80%. Treatment of enterocytes with polyclonal antibody against apolipoprotein A-I binding protein, a putative HDL receptor, inhibited both binding and degradation of [125I]HDL3 by these cells by 50%. Antibodies to apolipoprotein A-I, A-II and apo A-I-binding protein also inhibited [125I]HDL3 binding to cholesterol-loaded cells.
用针对载脂蛋白A-I和A-II的单特异性多克隆抗体处理125I标记的高密度脂蛋白（[125I]HDL3），分别导致[125I]HDL3与分离的人小肠上皮细胞的结合呈剂量依赖性抑制，抑制率分别为25%和50%。两种抗体还使[125I]HDL3的细胞内降解受到80%的抑制。用针对载脂蛋白A-I结合蛋白（一种假定的HDL受体）的多克隆抗体处理肠细胞，可使这些细胞对[125I]HDL3的结合和降解均受到50%的抑制。针对载脂蛋白A-I、A-II和载脂蛋白A-I结合蛋白的抗体也抑制[125I]HDL3与胆固醇负载细胞的结合。
